{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:28:19Z","timestamp":1790627299238,"version":"4.1.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00068","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T04:22:32Z","timestamp":1583295752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":73,"title":["Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm"],"prefix":"10.3389","volume":"7","author":[{"given":"S. Morteza","family":"Seyed Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schlapbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000488344","article-title":"A retrospective cohort study on patients with hidradenitis suppurativa","volume":"234","author":"Seyed Jafari","year":"2018","journal-title":"Dermatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.12680","article-title":"Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature","volume":"30","author":"Deckers","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1365-2230.1996.tb00145.x","article-title":"Hidradenitis suppurativa\u2013characteristics and consequences","volume":"21","author":"Jemec","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"J JAMA Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"61","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000453355","article-title":"Quality of life and psychosocial implications in patients with hidradenitis suppurativa","volume":"232","author":"Kouris","year":"2016","journal-title":"Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a study of 61 cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000477459","article-title":"Swiss practice recommendations for the management of hidradenitis suppurativa\/acne inversa","volume":"233","author":"Hunger","year":"2017","journal-title":"Dermatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: an update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B17","first-page":"584","article-title":"Hidradenitis suppurativa\u2014Management, comorbidities, and monitoring","volume":"46","author":"Vekic","year":"2017","journal-title":"Aust Fam Physician"},{"key":"B18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","article-title":"Hidradenitis suppurativa\/acne inversa: bilocated epithelial hyperplasia with very different sequelae","volume":"164","author":"von Laffert","year":"2011","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BTT.S199862.eCollection2019","article-title":"Systematic review of immunomodulatory therapies for hidradenitis suppurativa","volume":"13","author":"Lim","year":"2019","journal-title":"Biologics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019.eCollection2017","article-title":"Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study","volume":"133","author":"Canoui-Poitrine","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.det.2015.07.002","article-title":"The genetics of hidradenitis suppurativa","volume":"34","author":"Ingram","year":"2016","journal-title":"Dermatol Clin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/jid.2012.372","article-title":"\u03b3-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis","volume":"133","author":"Pink","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/jid.2012.162","article-title":"Mutations in the \u03b3-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa)","volume":"132","author":"Pink","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1126\/science.1196284","article-title":"Gamma-secretase gene mutations in familial acne inversa","volume":"330","author":"Wang","year":"2010","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/hmg\/ddy414","article-title":"Analysis of hidradenitis suppurativa\u2013linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages","volume":"28","author":"Li","year":"2019","journal-title":"Hum Mol Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamadermatol.2018.0141","article-title":"Association of hidradenitis suppurativa with T helper 1\/T helper 17 phenotypes","volume":"154","author":"Thomi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/exd.13482","article-title":"Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1\/Th17 immune response","volume":"27","author":"Thomi","year":"2018","journal-title":"Exp Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and non-lesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/ced.13959","article-title":"Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis","volume":"44","author":"Shanmugam","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/exd.12793","article-title":"The bacteriology of hidradenitis suppurativa: a systematic review","volume":"24","author":"Ring","year":"2015","journal-title":"Exp Dermatol"},{"key":"B38","first-page":"17","article-title":"Hidradenitis suppurativa: causes, features, and current treatments","volume":"11","author":"Vinkel","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jid.2018.09.036","article-title":"Are bacteria infectious pathogens in hidradenitis suppurativa? debate at the symposium for hidradenitis suppurativa advances meeting, November 2017","volume":"139","author":"Naik","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2340\/00015555-2503","article-title":"Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa","volume":"97","author":"Ring","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/exd.13885","article-title":"Bacterial biofilm is associated with higher levels of regulatory T cells in unaffected hidradenitis suppurativa skin","volume":"28","author":"Kjaersgaard Andersen","year":"2019","journal-title":"Exp Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/exd.12926","article-title":"Mechanical stress and the development of pseudo-comedones and tunnels in Hidradenitis suppurativa\/Acne inversa","volume":"25","author":"Boer","year":"2016","journal-title":"Exp Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jaad.2015.07.042","article-title":"Diet in the prevention of hidradenitis suppurativa (acne inversa)","volume":"73","author":"Danby","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B47","first-page":"239","article-title":"The role of androgens and estrogens in hidradenitis suppurativa\u2014a systematic review","volume":"24","author":"Riis","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"key":"B48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.it.2009.06.005","article-title":"The aryl hydrocarbon receptor in immunity","volume":"30","author":"Esser","year":"2009","journal-title":"Trends Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.lfs.2007.02.007","article-title":"Functional significance of non-neuronal acetylcholine in skin epithelia","volume":"80","author":"Hana","year":"2007","journal-title":"Life Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.4049\/jimmunol.1302412","article-title":"Cigarette smoke primes the pulmonary environment to IL-1\u03b1\/CXCR-2-dependent non-typeable Haemophilus influenzae-exacerbated neutrophilia in mice","volume":"193","author":"Nikota","year":"2014","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.18632\/oncotarget.13613","article-title":"Impacts of cigarette smoking on immune responsiveness: up and down or upside down?","volume":"8","author":"Qiu","year":"2017","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1038\/cti.2016.29.eCollection2016","article-title":"Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases","volume":"5","author":"Richards","year":"2016","journal-title":"Clin Transl Immunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/JIR.S86917.eCollection2016","article-title":"Hypoglycemic agents and potential anti-inflammatory activity","volume":"9","author":"Kothari","year":"2016","journal-title":"J Inflamm Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaad.2016.07.024","article-title":"Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study","volume":"76","author":"Vossen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2133.1995.tb02663.x","article-title":"Immunohistochemical evidence for differential distribution of 5 alpha-reductase isoenzymes in human skin","volume":"133","author":"Eicheler","year":"1995","journal-title":"T Br J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B57","first-page":"729","article-title":"Axillary Hyperhidrosis, Apocrine Bromhidrosis, Hidradenitis Suppurativa, and Familial Benign Pemphigus: Surgical Approach","volume-title":"Dermatologic Surgery.","author":"Hurley","year":"1989"},{"key":"B58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clindermatol.2016.10.018","article-title":"Treatments for hidradenitis suppurativa","volume":"35","author":"Andersen","year":"2017","journal-title":"Clin Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.08006.x","article-title":"S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa*(number ICD-10 L73","volume":"10","author":"Zouboulis","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]","volume":"21","author":"Patel","year":"2017","journal-title":"Curr Pain Headache Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.12788\/j.sder.2017.016","article-title":"Quality of life considerations and pain management in hidradenitis suppurativa","volume":"36","author":"Jemec","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1655524","article-title":"Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study","volume":"29","author":"Garcia-Martinez","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"B66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000329023","article-title":"Dapsone therapy for hidradenitis suppurativa: a series of 24 patients","volume":"222","author":"Yazdanyar","year":"2011","journal-title":"Dermatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/09546630600830588","article-title":"Hidradenitis suppurativa treated with dapsone: a case series of five patients","volume":"17","author":"Kaur","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol."},{"key":"B77","first-page":"44","article-title":"Finasteride in hidradenitis suppurativa: a \u201cmale\u201d therapy for a predominantly \u201cfemale\u201d disease","volume":"9","author":"Khandalavala","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0190-9622(99)70530-x","article-title":"Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa","volume":"40","author":"Boer","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/s0190-9622(84)70199-x","article-title":"Evaluation of isotretinoin treatment of hidradenitis suppurativa","volume":"11","author":"Dicken","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe Hidradenitis suppurativa\u2013A case series","volume":"27","author":"Anderson","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B81","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjd.14086","article-title":"Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients","volume":"174","author":"Nazary","year":"2016","journal-title":"Br J Dermatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1046\/j.1365-2230.2002.11125.x","article-title":"Methotrexate is of limited value in the treatment of hidradenitis suppurativa","volume":"27","author":"Jemec","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12788\/j.sder.2017.017","article-title":"Pathophysiology of hidradenitis suppurativa","volume":"36","author":"Hoffman","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"B84","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"B88","first-page":"S15","article-title":"A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa","volume":"11","author":"Sotiriou","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.dld.2016.09.010","article-title":"Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab","volume":"48","author":"Tursi","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","article-title":"Ustekinumab for hidradenitis suppurativa: a case report","volume":"105","author":"Santos-Perez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"B96","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794","article-title":"Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17a antibody secukinumab","volume":"98","author":"Schuch","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B100","first-page":"36","article-title":"Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.15368","article-title":"Guselkumab in the treatment of severe hidradenitis suppurativa","volume":"33","author":"Kovacs","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","article-title":"Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review","volume":"81","author":"Casseres","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1111\/1346-8138.14144","article-title":"Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection","volume":"45","author":"Takahashi","year":"2018","journal-title":"J Dermatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-5945-12-9","article-title":"A review of wide surgical excision of hidradenitis suppurativa","volume":"12","author":"Alharbi","year":"2012","journal-title":"BMC Dermatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0039-6109(02)00060-9","article-title":"Hidradenitis suppurativa","volume":"82","author":"Mitchell","year":"2002","journal-title":"Surg Clin North Am"},{"key":"B108","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0007-1226(03)00177-2","article-title":"Hidradenitis suppurativa: pathogenesis and management","volume":"56","author":"Slade","year":"2003","journal-title":"Br J Plast Surg"},{"key":"B109","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jaad.2015.07.043","article-title":"New and traditional surgical approaches to hidradenitis suppurativa","volume":"73","author":"Danby","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1097\/DSS.0000000000000806","article-title":"Surgical management of hidradenitis suppurativa: outcomes of 590 consecutive patients","volume":"42","author":"Kohorst","year":"2016","journal-title":"Dermatol Surg"},{"key":"B111","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","article-title":"Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions","volume":"63","author":"van der Zee","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B112","first-page":"5","article-title":"Step by step surgery: a new therapeutic proposal for hidradenitis suppurativa","volume-title":"Exp Dermatol","author":"Suppa","year":"2019"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T04:22:36Z","timestamp":1583295756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":112,"alternative-id":["10.3389\/fmed.2020.00068"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00068","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"article-number":"68"}}